Abstract: Dihydroartemisinin-piperaquine phosphate (P-ALAXIN®) is a fixed-dose artemisinin-based combination therapy (ACT). Despite the efficacy and tolerability of this drug, there are adverse effects associated with it. This study was designed to investigate potential toxicity of two different doses of the drug in rats.Thirty rats (Wistar strain) weighing 200±20g were completely randomised into three treatment groups; Group A (control), Group B (Therapeutic dose) and Group C (double therapeutic dose of P-ALAXIN®). Creatinine, Urea and Bilirubin levels were significantly (p<0.05) elevated in the plasma of the rats that received the two doses of P-ALAXIN ® by 67 and 117%; 33 and 67%; 85 and 119% respectively when compared to the control. Activities of plasma ALP, ALT, AST and GGT were also significantly (p<0.05) higher in the two treated group by 22 and 32%; 26and 36%; 18 and 34%; 43 and 91% respectively. Moreover, plasma Total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides in the two treated groups were significantly increase (p<0.05) by 24 and 38%; 38 and 75%; 37 and 88% and 28 and 64% respectively. These were accompanied by a significant (p<0.05) increase in the MDA level by 33 and 45% respectively in the two treated groups. Furthermore, the two doses of P-ALAXIN® significantly (p<0.05) reduced hepatic ascorbic acid and GSH by 44 and 58% and 44 and 75% respectively, with a concomitant reduction in activities of hepatic GST. Similarly, there was a significant reduction in the activities of hepatic Catalase, and SOD. These data indicate that therapeutic and double therapeutic doses of P-ALAXIN® has adverse effects on both enzymic and non-enzymic antioxidant status and induces marked renal and liver damages and oxidative stress in rats.
Keywords: Dihydroartemisinin-piperaquine phosphate,Therapeutic and Double therapeutic doses,Oxidative stress Renal and Liver damage.
[1] World Health Organization. Malaria Chemotherapy. Tech. Reg. Ser. Geneva, 1998.
[2] A. Djimdé, O.K. Doumbo, J.F. Cortese, K. Kayentao, S. Doumbo, Y. Diourté, A. Dicko, X.Z. Su, T. Nomura, D.A. Fidock, T.E. Wellems, C.V. Plowe, and D. Coulibaly, A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med., 344,2001, 299-302.
[3] N.J. White, Antimalarial drug resistance and combination chemotherapy,Philos. Trans. R. Soc. Lond. B. Biol. Sci., 354, 1999, 739–749.
[4] R.K. Haynes, Artemisinin and derivatives: The future for malaria treatment? Curr.Opin. Infect Dis., 14, 2001, 719-726.
[5] F. Nostenand N.J. White, Artemisinin-Based Combination Treatment of Falciparum Malaria,Am. J. Trop. Med. Hyg., 77,2007, 181-192.
[6] R.N. Price, V.M. Van, F. Nosten, C. Luxemburger, A. Brockman, L. Phaipun, T. Chongsuphajaisiddhi and N.J. White, Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria. Am. J. Trop. Med. Hyg., 59, 1998, 883-888. [7] H.M. McIntosh and P. Olliaro, Artemisinin derivatives for treating uncomplicated malaria. Cochrane Database System Review, CD000256(2)2000.
[8] N.J. White, Assessment of the pharmacodynamic properties of anti-malaria drugs in vivo. Antimicrob. Agents Chemother., 41, 1997, 1413- 1422.
[9] M.S. Mueller et al., "The Potential of Artemisia annua L. as a Locally-Produced Remedy for Malaria in the Tropics: Agricultural, Chemical and Clinical Aspects," J Ethnopharmacol, 73,2000, 487-493.
[10] N.J. White and P.L. Olliaro, Strategies for prevention of antimalarial drug resistance: rationale for combination therapy for malaria.Parasitol. Today,12, 1996, 399-401